According to the Complaint, Cancer Genetics, Inc. is an emerging leader in the field of personalized medicine, offering diagnostic products and services that enable precision medicine in the field of oncology.

The Complaint alleges that Defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Cancer Genetics had ineffective disclosure controls and internal controls over financial reporting; and (2) as a result, Defendants’ statements about the Company’s business, operations and prospects were materially false and misleading and/or lacked a reasonable bases at all relevant times.

On August 27, 2018, the Court issued an Order consolidating cases and appointing Lead Plaintiff and Counsel. The consolidated cases shall be identified as "In re Cancer Genetics, Inc. Securities Litigation." Lead Plaintiff filed an amended Complaint on October 30. Defendants filed a Motion to Dismiss the amended Complaint on December 31. On February 25, 2020, the Court granted Defendants' Motion to Dismiss and dismissed the case with prejudice.